The Technical AnalystExchange: SIX Industry: Pharmaceuticals, Biotechnology & Life Sciences
Obseva SA Price, Forecast, Insider, Ratings, Fundamentals & Signals
-11.11% CHF0.0064
America/New_York / 30 apr 2024 @ 11:31
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 0.940 mill |
| EPS: | -0.290 |
| P/E: | -0.0200 |
| Earnings Date: | May 13, 2024 |
| SharesOutstanding: | 146.92 mill |
| Avg Daily Volume: | 0.547 mill |
| RATING 2024-04-30 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Buy | |
| P/E: | Sell | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 1/22 | 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | |
| Revenue | n/a | n/a | n/a | n/a | ||
| Gr.Profit | n/a | n/a | n/a | n/a | ||
| Ebit | n/a | |||||
| Asset | n/a | |||||
| Debt | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.0200 | sector: PE 25.29 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.00x |
| Company: PE -0.0200 | industry: PE 17.08 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
CHF 0.0024 - 0.0104 ( +/- 62.50%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 |
| Volume Signals | |
|---|---|
| Price | CHF0.0064 (-11.11% ) |
| Volume | 0.157 mill |
| Avg. Vol. | 0.547 mill |
| % of Avg. Vol | 28.70 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For OBSN.SW
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
OBSN.SW
ObsEva SA, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin releasing hormone receptor antagonist that is in Phase III clinical trial for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. The company is also involved in developing Ebopiprant, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, which is in Phase II clinical trial as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age; and Nolasiban, an oral oxytocin receptor antagonist that is in Phase I clinical trial to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization. ObsEva SA was founded in 2012 and is headquartered in Geneva, Switzerland.